News
4mon
Zacks.com on MSNAstraZeneca Rises Almost 9% in a Month: How to Play the StockAstraZeneca boasts a diversified geographical footprint as well as a product portfolio with several blockbuster medicines.
Hosted on MSN1mon
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?AstraZeneca boasts a diversified geographical footprint as well as a product portfolio with several blockbuster medicines. AstraZeneca now has 16 blockbuster medicines in its portfolio with sales ...
One of the key ways in which AI has transformed AstraZeneca's research is in the discovery and design of drugs. Historically, medicines have been discovered and designed manually by scientists in ...
rare disease and heart disease medicines. Sales in AstraZeneca's top business, oncology, grew 19% at constant currency rates to $5.33 billion and accounted for 41% of the total, while its rare ...
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop ...
Some drugmakers are taking the unusual step of sending more medicines by air to the U.S ... drug maker Novo Nordisk and Anglo-Swedish AstraZeneca. The European health care sub-index was ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results